Total revenues rose 6% in constant exchange rates in H1 to USD 30.7 billion, while core earnings per share increased 11% to USD 5.21. For the second quarter, total revenues were USD 15.4 billion, up 5% in constant exchange rates, and core EPS rose 18% to USD 2.63.

The company said strong double-digit growth in oncology and rare disease offset headwinds from Farxiga losing exclusivity in the US and China’s volume-based procurement program. AstraZeneca also raised its half-year dividend by 3 cents to USD 1.06 per share.

“Our first half performance was strong, with continued delivery from our R&D pipeline,” CEO Pascal Soriot says. He highlights six positive Phase III readouts and eight first approvals in major markets, including the US approval of Baxfendy for hypertension.

AstraZeneca confirmed its 2026 guidance for total revenues and core EPS in constant exchange rates, forecasting mid- to high-single-digit revenue growth and low double-digit core EPS growth.

The company also reported a series of recent regulatory and clinical milestones, including major approvals for medicines such as Datroway, Enhertu, Etcamah and Imfinzi, as well as new licensing deals in China and the US.